Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Renal Cancer: early-phase trial registry
15 of 30 indexed Renal Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #519 of 28,707 conditions by registered trial count.
30 US clinical trials · 15 currently recruiting · #519 of 28,707 conditions by registered trial count
Renal Cancer: 30 US clinical trials tracked, 15 recruiting.
Renal Cancer is the subject of 30 registered US clinical trials on ClinicalTrials.gov, 15 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 15 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 7 of these trials.
Enrollment posture brief
Registry condition renal-cancer
OPEN 15 | RECR 50% | LATE 2 | EARLY 15 | RANK #519 | SPON 7
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Renal Cancer lists 15 open slots (50% of 30 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Renal Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Renal Cancer is recruiting above its size-band peers.
15 of 30 indexed trials (50%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Renal Cancer research.
Memorial Sloan Kettering Cancer Center accounts for 7 of 30 trials (23.3%). 21 distinct sponsors appear on at least one study for this condition label.
-
Typical Renal Cancer enrolment sits around 119 participants.
Median target enrolment is 119 among the 30 trials that report a genuine target (sentinel values excluded). 13 of those (43.3%) plan for fewer than 100 participants.
-
Renal Cancer research is mostly interventional.
23 interventional and 7 observational studies make up this index (76.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
30 total, page 1 of 1
Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies
National Cancer Institute (NCI)
NCT01109394
Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease
National Cancer Institute (NCI)
NCT00026884
Video Education With Result Dependent dIsclosure
Dana-Farber Cancer Institute
NCT05225428
Kidney Cancer DNA Registry
Memorial Sloan Kettering Cancer Center
NCT02087852
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
Memorial Sloan Kettering Cancer Center
NCT00582621
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Apollomics
NCT03175224
Stereotactic Magnetic Resonance Guided Radiation Therapy
Dana-Farber Cancer Institute
NCT04115254
A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
Pfizer
NCT07227415
A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
Nuvectis Pharma
NCT05873686
NSAID Use After Robotic Partial Nephrectomy
University of Miami
NCT05842044
64Cu-GRIP B in Patients With Advanced Malignancies
Rahul Aggarwal
NCT05888532
Advanced Diffusion Imaging in Renal Cancer Patients
NYU Langone Health
NCT06116253
Decision Aid (DA) for Renal Patients
NYU Langone Health
NCT05387863
Intra-procedural Spectral CT for Image-guided Embolization and Ablation in Interventional Oncology
Palo Alto Veterans Institute for Research
NCT07303725
Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus
University of Colorado, Denver
NCT05969496
9-ING-41 in Patients with Advanced Cancers
Actuate Therapeutics
NCT03678883
Ablation of Renal Masses Outcomes Registry (ARMOR): Ablation Procedure and Quality of Life Assessment
Memorial Sloan Kettering Cancer Center
NCT01888198
A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
NCT03634540
Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)
Toni Choueiri, MD
NCT03203473
A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors
Memorial Sloan Kettering Cancer Center
NCT03693014
The HistoSonics Edison™ System for Treatment of Primary Solid Renal Tumors Using Histotripsy (#HOPE4KIDNEY)
HistoSonics
NCT05820087
Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma
Memorial Sloan Kettering Cancer Center
NCT01582204
Mannitol Use During Partial Nephrectomy Prior to Renal Ischemia and Impact on Renal Function Outcomes
Memorial Sloan Kettering Cancer Center
NCT01606787
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
Amgen
NCT00531284
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
Dan Zandberg
NCT04157985
High-dose Bevacizumab in Advanced Renal Carcinoma Patients
SCRI Development Innovations
NCT00455975
Feasibility of a Consumer Based Accelerometer in Monitoring Outpatient Physical Activity: A Study in Patients With Cancer and Amyotrophic Lateral Sclerosis
Duke University
NCT02457715
A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies
Bristol-Myers Squibb
NCT00441337
Preliminary Evaluation of Uptake of [68Ga]P16-093 in Metastatic Prostate and Renal Cancer
Five Eleven Pharma
NCT03073395
Pilot Evaluation of 124I-Iodo-Azomycin Galacto-Pyranoside (*IAZGP) Positron Emission Tomography (PET) in the Imaging of Hypoxic Tumors
Memorial Sloan Kettering Cancer Center
NCT00588276
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 7 |
| Phase 2 | 8 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Renal Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Renal Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Renal Cancer page
30 registered trials, 15 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 15 Renal Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Renal Cancer trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Renal Cancer condition card totals 30 registered trials; most-linked intervention [68Ga]P16-093; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.